All In Biotech

Drug Trial Radar · NCT07607925

A Study to Evaluate Safety and Clinical Activity of GSK5926371 in Adult Participants With Relapsed or Refractory B-NHL

A Phase 1/2 Open-label, Multi-center Study to Evaluate the Safety and Clinical Activity of GSK5926371 in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)

Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

49

Planned (sponsor's estimate)

Start

Jun 19, 2026

Primary completion

Jan 10, 2030

Study completion Jan 10, 2030

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
May 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if drug GSK5926371 works to treat a form of B-cell cancer (a type of blood cancer) that has returned or failed to respond to prior therapies in adults. The study will primarily assess the drugs safety and tolerability in participants. Additionally, it seeks to determine the clinical efficacy and pharmacokinetic (PK) properties of GSK5926371.

Conditions

  • Lymphoma, Non-Hodgkin

Interventions

  • GSK5926371Drug

    GSK5926371 will be administered at different dose levels.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with dose limiting toxicities (DLTs)Time frame: Up to 28 days
  2. Number of participants with adverse events (AEs) or Serious adverse events (SAEs) by severityTime frame: Up to approximately 169 weeks

Locations

22 sites in 8 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Iowa City, Iowa · Recruiting

  • GSK Investigational Site

    New York, New York · Recruiting

  • GSK Investigational Site

    Canton, Ohio · Recruiting

  • GSK Investigational Site

    Heidelberg, Victoria, Australia · Recruiting

  • GSK Investigational Site

    Toronto, Ontario, Canada · Recruiting

  • GSK Investigational Site

    Helsinki, Finland · Recruiting

  • GSK Investigational Site

    Tampere, Finland · Recruiting

  • GSK Investigational Site

    Pierre-Bénite, France · Recruiting

  • GSK Investigational Site

    Rennes, France · Recruiting

  • GSK Investigational Site

    Villejuif, France · Recruiting

  • GSK Investigational Site

    Alessandria, Italy · Recruiting

  • GSK Investigational Site

    Milan, Italy · Recruiting

  • GSK Investigational Site

    Rozzano, MI, Italy · Recruiting

  • GSK Investigational Site

    Aichi, Japan · Recruiting

  • GSK Investigational Site

    Chiba, Japan · Recruiting

  • GSK Investigational Site

    Tokyo, Japan · Recruiting

  • GSK Investigational Site

    Barcelona, Spain · Recruiting

  • GSK Investigational Site

    Barcelona, Spain · Recruiting

  • GSK Investigational Site

    Madrid, Spain · Recruiting

  • GSK Investigational Site

    Madrid, Spain · Recruiting

  • GSK Investigational Site

    Salamanca, Spain · Recruiting

  • GSK Investigational Site

    Valencia, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.